Clinical Topics & News
News
FDA expands atogepant approval to include chronic migraine
The approval makes atogepant the first, and only, oral CGRP receptor antagonist approved to prevent migraine across frequencies, including...
News
Headache before the revolution: A clinician looks back
To celebrate our 30th year in print, Neurology Reviews invited experts to look back on 30 years of progress in their subspecialty. In this...
News
Migraine after concussion linked to worse outcomes
Although most children recover quickly from a concussion, approximately one-third continue to report symptoms a month after the event.
News
How a concussion led a former football player/WWE star to a pioneering neuroscience career
The NIH and the CDC are now in agreement about the risks of participating in impact sports and activities.
News
Migraine in children and teens: managing the pain
Getting adequate sleep, staying hydrated, and managing stress can help reduce the intensity and frequency of migraine attacks in adolescents.
News
Will the headache field embrace rofecoxib?
The drug formerly known as Vioxx, withdrawn in 2004 over cardiovascular safety concerns, may be given new life as an acute treatment for migraine...
News
FDA okays new oral CGRP antagonist for migraine prevention
With this approval, neurologists will be able to choose from four monoclonal antibodies and two gepants for the preventive treatment of migraine...
Clinical Topics & News
Devices for the treatment of migraine
News
FDA expands rimegepant indication to include migraine prevention
Rimegepant is currently the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks.